Supplementary Material for: Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions

<b><i>Background/Aims:</i></b> To assess the efficacy and tolerability of the new aerosol foam of calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g (Cal/BD foam, Enstilar®) in psoriasis vulgaris under daily practice conditions. <b><i>Methods:</i></b> 410 adult psoriasis patients (56% male) from 87 German sites were enrolled in a 4-week, open-label, prospective, non-controlled, observational, non-interventional study. <b><i>Results:</i></b> At baseline, patients presented with a psoriasis severity of mild (41.81%), moderate (49.63%), and severe (8.31%) assessed by an investigator global assessment (IGA). After 4 weeks of treatment, 49% of the patients achieved an IGA of clear/almost clear. The mean affected body surface area was reduced from 12.91 to 7.55%, the PASI from 10.4 to 5.2 (<i>p</i> &lt; 0.0001). 43% of the patients with severe IGA achieved treatment success (IGA = 0/1 and ≥2-step improvement). 93% of the patients did not show any adverse events. <b><i>Conclusion:</i></b> The new Cal/BD foam showed a convincing efficacy and tolerability profile in daily practice, particularly in patients with severer disease manifestations.

<b><i>背景与目的：</i></b> 评估新型卡泊三醇50 μg/g+二丙酸倍他米松0.5 mg/g气溶胶泡沫制剂（Cal/BD泡沫，Enstilar®）在日常临床实践中治疗寻常型银屑病的疗效与耐受性。<b><i>方法：</i></b> 纳入来自德国87家研究中心的410名成年银屑病患者（男性占比56%），开展一项为期4周的开放标签、前瞻性、非对照、观察性非干预研究。<b><i>结果：</i></b> 基线时，经研究者整体评估（investigator global assessment, IGA），患者的银屑病严重程度分布为轻度（41.81%）、中度（49.63%）及重度（8.31%）。经4周治疗后，49%的患者达到IGA评分清除/几乎清除状态。患者平均受累体表面积从12.91%降至7.55%，银屑病面积与严重程度指数（Psoriasis Area and Severity Index, PASI）从10.4降至5.2（p < 0.0001）。43%的重度IGA评分患者实现治疗成功（IGA评分0/1分且较基线提升≥2个等级）。93%的患者未出现任何不良事件。<b><i>结论：</i></b> 这款新型Cal/BD泡沫制剂在日常临床实践中展现出令人信服的疗效与耐受性特征，尤其针对病情较为严重的患者群体。